Salesforce Shares Decline Amid Software Sector Pressure and AI Concerns

The Motley FoolThe Motley Fool
|||1 min read
Key Takeaway

Salesforce shares fell 3.86% amid software sector weakness and AI disruption concerns. Stock hits 52-week low as investors await earnings guidance on AI impact.

Salesforce Shares Decline Amid Software Sector Pressure and AI Concerns

Salesforce stock declined 3.86% during today's trading session, reflecting broader weakness across the software sector as investors reassess valuations amid mounting macroeconomic concerns. The selloff was catalyzed by a viral research report from Citrini Research outlining potential AI-driven economic disruption by 2028, compounded by escalating trade tensions and the introduction of a new artificial intelligence product from Anthropic that may impact enterprise software demand.

The market's negative sentiment extended to analyst sentiment, with two research firms adjusting their price targets downward while maintaining buy-equivalent ratings on the stock. These adjustments underscore analyst expectations for near-term headwinds, though long-term conviction remains intact. Salesforce shares have now reached a 52-week low and have declined 33 percent year-to-date, reflecting a significant correction from earlier valuations.

Market participants are focused on the company's fourth-quarter earnings report scheduled for Tuesday, where management commentary on artificial intelligence disruption and its impact on enterprise software demand will likely be closely scrutinized. The results will provide insight into whether current market concerns are fully priced into the stock or if additional pressure may emerge.

Source: The Motley Fool

Back to newsPublished Feb 23

Related Coverage

GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
Investing.com

D-Wave's 44% Plunge Masks Quantum Leap: Growth Story vs. Valuation Reality

D-Wave ($QBTS) fell 44% in 2026 despite strong bookings exceeding 2025 totals and $30M in major deals. Analysts see 132% upside, but 237x sales valuation remains extreme.

QBTS
GlobeNewswire Inc.

OneMain Holdings Faces Multi-State Securities Probe Over Alleged Lending Fraud

Pomerantz Law Firm investigates $OMF following multi-state lawsuit alleging deceptive lending practices. Stock tumbles 5.38% on fraud allegations.

OMF
GlobeNewswire Inc.

Boston Scientific Faces Securities Fraud Lawsuit Over Overstated EP Growth Claims

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

BSX
GlobeNewswire Inc.

Nektar Therapeutics Faces Class Action Over Failed Trial Data Disclosure

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

NKTR
GlobeNewswire Inc.

Pomerantz Files Securities Fraud Suit Against $INO Over FDA Approval Misstatements

Pomerantz LLP sues Inovio Pharmaceuticals for alleged securities fraud over FDA approval misstatements. Stock fell 3.1% and 24.45% following manufacturing delays and accelerated approval rejection.

INO